Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares ...

For children with atopic dermatitis (AD), early childhood stressful life events are associated with an increased risk for disease activity, according to a study published online Jan. 28 in the Journal ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Read on to learn more about resting heart rate including normal resting heart rates based on age, target heart rate zones during activity and red flags to consider, plus causes of an elevated ...

All products are independently selected by our editors. If you buy something, we may earn an affiliate commission. On a good day, your skin might be calm and glowy—but if you’re dealing with ...

The European Medicines Agency (EMA) currently approves dupilumab use for moderate to severe AD in patients aged 12 years and older non-responsive to conventional treatment and for AD children of 6–11 ...

Last September, the FDA approved Ebglyss for the treatment of eczema. With less frequent dosing, Ebglyss is expected to compete fiercely with Dupixent, a treatment that racked up over $13 billion ...

The UK's communications regulator has published guidance for website operators aimed at preventing under-18s from accessing pornographic content online via "highly effective age assurance" techniques.

Medicare covers medically necessary treatment for eczema. This includes medicated creams and pills, dupilumab (Dupixent) injections, and phototherapy. Original Medicare with a Part D plan or an ...